title: Rituximab therapy for refractory idiopathic scleritis.
abstract: OBJECTIVE
  To report 2 cases of refractory idiopathic scleritis treated with rituximab.
  
  
  METHODS
  Interventional case series.
  
  
  RESULTS
  Case 1: A 54-year-old woman, presented with anterior idiopathic scleritis in her right eye. Treatment with systemic steroids was not effective. Intravenous cyclophosphamide was discontinued after an adverse event. Case 2: A 43-year-old woman presented with idiopathic posterior scleritis in her left eye. Initial treatment with steroids was ineffective. In both cases, long-lasting remission without further relapses was achieved after 4 weekly doses (375 mg/m(2)) of rituximab.
  
  
  CONCLUSIONS
  Rituximab was found to be an effective treatment for refractory idiopathic anterior and posterior scleritis.
authors.forename: Katherine
authors.initials: K
authors.lastname: Bogdanic-Werner
authors.forename: Guillermo
authors.initials: G
authors.lastname: Fernandez-Sanz
authors.forename: Nicolás
authors.initials: N
authors.lastname: Alejandre Alba
authors.forename: Patricia
authors.initials: P
authors.lastname: Ferrer Soldevila
authors.forename: Fredeswinda I
authors.initials: FI
authors.lastname: Romero-Bueno
authors.forename: Olga
authors.initials: O
authors.lastname: Sanchez-Pernaute
mesh_terms: D000328:Adult; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018951:Antigens, CD20; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008875:Middle Aged; D000069283:Rituximab; D015423:Scleritis / Q000175:diagnosis / Q000188:drug therapy*; D041623:Tomography, Optical Coherence
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D007155:Immunologic Factors; D000069283:Rituximab